Stockscreener 앱 받기
277.64
2.58%
-7.34
시간 외 거래:
277.64
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com
(MDGL) Investment Analysis - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(MDGL) On The My Stocks Page - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK
Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha
A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com
Will Other Major MASH Deals Follow GSK/Boston Pharma? - insights.citeline.com
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com
Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com
Where are the Opportunities in (MDGL) - news.stocktradersdaily.com
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times
Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha
Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey
What is B. Riley’s Estimate for MDGL FY2028 Earnings? - Defense World
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com
Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
1.06%
1.67%
자본화:
|
볼륨(24시간):